Dr. Antoni Chan synovialjoints
5 years ago
In this longitudinal observational cohort study, AAU was the most frequent EAM to develop. No impact of gender or disease activity on the development of any EAM @RheumNow #ACR20 Abstr#1312 https://t.co/RTwWoS9sgX
Dr. John Cush RheumNow
5 years ago
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
https://t.co/Wyeh8pu3ax https://t.co/oCdfywJUoo
Dr. Antoni Chan synovialjoints
5 years ago
Detection of inflammatory back pain (IBP) is important for the early diagnosis of Axial SpA. Which IBP criteria do you use in your clinic? @RheumNow #ACR20 Abst#1303
Robert B Chao, MD doctorRBC
5 years ago
Pregnancy outcomes in women with AxSpA
4 prospective cohorts in Europe
328 total pregnancies
Favorable outcomes overall
1⃣3% pre-eclampsia
2⃣6-9% gestational DM
3⃣0-5% preterm birth rates (similar to WHO rate 9% in Eur)
@RheumNow #ACR20 Abs#1498
David Liew drdavidliew
5 years ago
COVID-19 changes everything, but our vasculitis patients particularly have had some really difficult decisions to make.
@VasculitisFound @michaelgeorgemd @maferradastrong @petercgrayson @RADoctor @DrPeterMerkel et al
#ACR20 ABST1416 @RheumNow https://t.co/lWXtgSqDqy
Dr. Antoni Chan synovialjoints
5 years ago
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Dr. John Cush RheumNow
5 years ago
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
David Liew drdavidliew
5 years ago
In the current era, would a positive treat-to-target study in AS change your approach to practice?
(TICOSPA trial ABST1444) #ACR20 @RheumNow
Dr. Rachel Tate uptoTate
5 years ago
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate
5 years ago
Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU
David Liew drdavidliew
5 years ago
We're getting better at treating vasculitis over time.
In-hospital mortality in pts primarily admitted with vasculitis is got much closer to all-comers 1998-2014 (US NIS). Hopefully with more new meds, we've closed the gap even more since!
@UABRheum #ACR20 ABST1423 @RheumNow https://t.co/kNq8HCjqQ0
Dr. Rachel Tate uptoTate
5 years ago
Dr. Crow's #StateoftheArt lecture revealed that BEL may be best used in pts with < 2 years and SLEDAI >10 based on the study from Gatto, M et al from 2020. Does this change how you will use BEL in your practice? #ACR20 @RheumNow
David Liew drdavidliew
5 years ago
Can hs-troponin and hsCRP predict future major cardiovascular events? Certainly appears so in RA pts (n=636).
To what extent do subclinical dx and inflammation combine to cause future RA CV pain?
PRECISION trial subgroup @ElaineHusniMD @DanielHSolomon #ACR20 ABST1189 @RheumNow https://t.co/ZYTpodatVI
Potpourri of Pathotypes of Predictors with RA Faculty
Dr. Jonathan Kay again leads an international panel of rheumatologists to elicit their opinions on key abstracts at ACR 2020. Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.
Outpatient Billing and Coding Pearls: Dr Rachel Tate
Dr. Rachel Tate reviews outpatient billing and coding pearls presented at a session at the 2020 ACR annual meeting.
Poster Hall